W15QKN21C0014 — REGENERON PHARMACEUTICALS INC — Department of Defense ($5,565,000,000)

PRODUCTION OF THERAPEUTIC IN SUPPORT OF NATIONAL EMERGENCY RESPONSE TO CORONAVIRUS 2019 (COVID-19): IN SUPPORT OF OPERATION WARP SPEED (OWS), THE GOVERNMENT IS PURCHASING UP TO 1,250,000 DOSES OF THE EMERGENCY USE AUTHORIZATION (EUA) THERAPEUTIC. Recipient: REGENERON PHARMACEUTICALS INC Obligated amount: $5,565,000,000 Awarding agency: Department of Defense (Department of the Army) Procurement instrument identifier (PIID): W15QKN21C0014 Start date: 2021-01-12 End date: 2022-07-31

Related documents

• FA872623FB094 — EXPANSIA GROUP LLC — Department of Defense ($74,633,980)#601476
• HHSO100201700016C — REGENERON PHARMACEUTICALS INC — Department of Health and Human Services ($695,741,476)#605719
• W911QY21C0016 — ELI LILLY AND COMPANY — Department of Defense ($1,373,930,000)#604860
• 0033 — SCIENCE APPLICATIONS INTERNATIONAL CORPORATION — Department of Defense ($759,925,145)#605564
• W15P7T06CT004 — LOCKHEED MARTIN CORPORATION — Department of Defense ($724,062,462)#605641